Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression

Sleep. 1995 Jul;18(6):470-7.

Abstract

Paroxetine (30 mg), a selective serotonin (5-HT) reuptake inhibitor, was compared in a double-blind trial to amitriptyline (150 mg) in a sample of 40 inpatients aged 18-65 years who fulfilled Research Diagnostic Criteria for major depression. Patients were studied after a placebo drug washout period of 10 days and after an active 4-week treatment period. Sleep EEG recordings were performed before and at the end of the study as well as during acute treatment (first 2 days) and following withdrawal of active medication. Paroxetine shows an antidepressant effect similar to amitriptyline with a different side-effect profile typical of 5-HT reuptake inhibition. Paroxetine and amitriptyline decreased the amount of REM sleep, a well-known effect of classical antidepressants. Paroxetine also shared with other 5-HT reuptake inhibitors an alerting effect on sleep that was not shown to be detrimental on subjective sleep quality.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Amitriptyline / pharmacology
  • Amitriptyline / therapeutic use*
  • Antidepressive Agents / therapeutic use*
  • Depressive Disorder / drug therapy*
  • Double-Blind Method
  • Electroencephalography / drug effects
  • Humans
  • Male
  • Middle Aged
  • Paroxetine / adverse effects
  • Paroxetine / pharmacology
  • Paroxetine / therapeutic use*
  • Polysomnography
  • Selective Serotonin Reuptake Inhibitors / therapeutic use*
  • Sleep Stages / drug effects
  • Sleep, REM / drug effects
  • Wakefulness / drug effects

Substances

  • Antidepressive Agents
  • Serotonin Uptake Inhibitors
  • Amitriptyline
  • Paroxetine